Endothelial function in health and disease: New insights into the genesis of cardiovascular disease

American Journal of Medicine

Volumn 105, Issue 1 A, 1998, Pages 32S-39S

  Quyyumi, Arshed A ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC OXIDE;

AGING; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIABETES MELLITUS; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; SMOKING; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; VASCULAR ENDOTHELIUM;

EID: 0032490711     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(98)00209-5     Document Type: Conference Paper

References (73)

1. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:1980;373-376.
2. Feletou M., Vanhoutte P.M. Endothelium-dependent hyperpolarization of canine coronary smooth muscle. Br J Pharmacol. 93:1988;515-524.
3. Palmer R.M., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 327:1987;524-526.
4. Förstermann U., Neufang B. The endothelium-dependent vasodilator effect of acetylcholine characterization of the endothelial relaxing factor with inhibitors of arachidonic acid metabolism . Eur J Pharmacol. 103:1984;65-70.
5. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.
6. Miller V.M., Vanhoutte P.M. Endothelium-dependent contractions to arachidonic acid are mediated by products of cyclooxygenase. Am J Physiol. 248:1985;H432-H437.
7. Katusic Z.S., Vanhoutte P.M. Superoxide anion is an endothelium-derived contracting factor. Am J Physiol. 257:1989;H33-H37.
8. Quyyumi A.A. Circadian variation in myocardial ischemia pathophysiologic mechanisms . Stern S. Silent Myocardial Ischemia. 1998;159-174 Martin Dunitz, Ltd, London.
9. Ohara Y., Peterson T.E., Harrison D.G. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 91:1993;2546-2551.
10. Nakazono K., Watanabe N., Matsuno K., et al. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA. 88:1991;10045-10048.
11. Cybulsky M.I., Gimbrone M.A. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 251:1991;788-791.
12. Rubanyi G.M. The role of endothelium in cardiovascular homeostasis and diseases. Cardiovasc Pharmacol. 22:(suppl 4):1993;S1-S14.
13. Busse R., Fleming I. Regulation and functional consequences of endothelial nitric oxide formation. Ann Med. 27:1995;331-340.
14. Schini-Kerth V.B., Vanhoutte P.M. Nitric oxide synthases in vascular cells. Exp Physiol. 80:1995;885-905.
15. Holtz J., Förstermann U., Pohl U., et al. Flow-dependent, endothelum-mediated dilation of epicardial coronary arteries in conscious dogs effects of cyclooxygenase inhibition . J Cardiovasc Pharmacol. 6:1984;1161-1169.
16. Werner-Felmayer G., Werner E.R., Fuchs D., et al. Tetrahydrobiopterin-dependent formation of nitrite and nitrate in murine fibroblasts. J Exp Med. 172:1990;1599-1607.
17. Harrison D.G., Sayegh H., Ohara Y., et al. Regulation of expression of the endothelial cell nitric oxide synthase. Clin Exp Pharmacol Physiol. 23:1996;251-255.
18. Diodati JG, Dakak N, Gilligan DM, Quyyumi AA. Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans. Circulation. (in press).
19. Armstead V.E., Minchenko A.G., Schuhl R.A., et al. Regulation of P-selectin expression in human endothelial cells by nitric oxide. Am J Physiol. 273:1997;H740-H746.
20. Celermajer D.S., Sorenson K.E., Spiegelhalter D.J., et al. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol. 24:1994;471-476.
21. Anderson T.J., Uehata A., Gerard M.D., et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 26:1995;1235-1241.
22. Quyyumi A.A., Husain S., Mulcahy D., et al. Nitric oxide activity in the human coronary and peripheral circulation. (Abstr.) Circulation. 92:1995;I-769.
23. Hirooka Y., Egashira K., Imaizumi T., et al. Effect of L-arginine on acetylcholine-induced endothelium-dependent vasodilation differs between the coronary and forearm vasculatures in humans. J Am Coll Cardiol. 24:1994;948-955.
24. Yeung A.C., Vekshtein V.I., Krantz D.S., et al. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med. 325:1991;1551-1556.
25. Quyyumi A.A., Dakak N., Andrews N.P., et al. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation. 92:1995;320-326.
26. Zeiher A.M., Drexler H., Wollschläger H., Just H. Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. Circulation. 84:1991;1984-1992.
27. Drexler H., Zeiher A.M., Wollschlager H., et al. Flow-dependent coronary artery dilatation in humans. Circulation. 80:1989;466-474.
28. Quyyumi A.A., Mulcahy D., Andrews N.P., et al. Coronary vascular nitric oxide activity in hypertension and hypercholesterolemia comparison of acetylcholine and substance P . Circulation. 95:1997;104-110.
29. Casino P.R., Kilcoyne C.M., Quyyumi A.A., et al. Investigation of decreased availability of nitric oxide precurser as the mechanism responsible for impaired endothelium-dependent vasodilation in hypercholesterolemic patients. J Am Coll Cardiol. 23:1994;844-850.
30. Panza J.A., Casino P.R., Badar D.M., Quyyumi A.A. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation. 87:1993;1475-1481.
31. Gilligan D.M., Guetta V., Panza J.A., et al. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation. 90:1994;35-41.
32. Panza J.A., Garcia C.E., Kilcoyne C.M., et al. Impaired endothelium-dependent vasodilation in patients with essential hypertension evidence that nitric oxide abnormality is not localized to a single signal transduction pathway . Circulation. 91:1995;1732-1738.
33. Quyyumi A.A., Dakak N., Andrews N.P., et al. Nitric oxide activity in the human coronary circulation impact of risk factors for coronary atherosclerosis . J Clin Invest. 95:1995;1747-1755.
34. Quyyumi A.A., Dakak N., Mulcahy D., et al. Nitric oxide activity in the atherosclerotic human coronary circulation. J Am Coll Cardiol. 29:1997;308-317.
35. Quyyumi A.A., Cannon R.O. III, Panza J.A., et al. Endothelial dysfunction in patients with chest pain and normal coronary arteries. Circulation. 86:1992;1864-1871.
36. Egashira K., Inou T., Hirooka Y., et al. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest. 91:1993;29-37.
37. Ludmer P.L., Selwyn A.P., Shook T.L., et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 315:1986;1046-1051.
38. Vita J.A., Treasure C.B., Nabel E.G., et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 81:1990;491-497.
39. Anderson T.J., Meredith I.T., Charbonneau F., et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation. 93:1996;1647-1650.
40. Witztum J.L. The oxidation hypothesis of atherosclerosis. Lancet. 344:1994;793-795.
41. Arnal J.-F., Münzel T., Venema R.C., et al. Interactions between L-arginine and L-glutamine change endothelial NO production an effect independent of NO synthase substrate availability . J Clin Invest. 95:1995;2565-2572.
42. Dakak N, Husain S, Mulcahy D, et al. Contribution of nitric oxide to reactive hyperemia: impact of endothelial dysfunction. Hypertension. (in press).
43. Treasure C.B., Klein J.L., Weintraub W.S., et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 332:1995;481-487.
44. Anderson T.J., Meredith I.T., Yeung A.C., et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 332:1995;488-493.
45. Panza J.A., Quyyumi A.A., Callahan T.S., Epstein S.E. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol. 21:1993;1145-1151.
46. Levine G.N., Frei B., Koulouris S.N., et al. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 93:1996;1107-1113.
47. Gilligan D.M., Sack M.N., Guetta V., et al. Effect of antioxidant vitamins on low density lipoprotein oxidation and impaired endothelium-dependent vasodilation in patients with hypercholesterolemia. J Am Coll Cardiol. 24:1994;1611-1617.
48. Garcia C.E., Kilcoyne C.M., Cardillo C., et al. Evidence that endothelial dysfunction in patients with hypercholesterolemia is not due to increased extracellular nitric oxide breakdown by superoxide anions. Am J Cardiol. 76:1995;1157-1161.
49. Garcia C.E., Kilcoyne C.M., Cardillo C., et al. Effect of copper-zinc superoxide dismutase on endothelium-dependent vasodilation in patients with essential hypertension. Hypertension. 26:1995;863-868.
50. Cardillo C., Kilcoyne C.M., Cannon R.O., et al. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension. 30:1997;57-63.
51. Stamler J.S., Slivka A. Biological chemistry of thiols in the vasculature and in vascular-related disease. Nutr Rev. 54:1996;1-30.
52. Keaney J.F. Jr, Simon D.I., Stamler J.S., et al. NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties. J Clin Invest. 91:1993;1582-1589.
53. Prasad A., Pader F., Andrews N.P., et al. Glutathione and N-acetylcysteine improve endothelial dysfunction in humans. (Abstr.) Circulation. ((suppl 1)):1977;1-251.
54. de Belder A.J., MacAllister R., Radomski M.W., et al. Effects of S-nitroso-glutathione in the human forearm circulation evidence for selective inhibition of platelet activation . Cardiovasc Res. 28:1994;691-694.
55. Horowitz J.D., Antman E.M., Lorell B.H., et al. Potentiation of the cardiovascular effects of nitroglycerin by N-acetylcysteine. Circulation. 68:1983;1247-1253.
56. Horowitz J.D., Henry C.A., Syrjanen M.L., Louis W.J., Fish R.D., Smith T.W., Antman E.M. Combined use of nitroglycerin and N-acetylcysteine in the management of unstable angina pectoris. Circulation. 77:1998;787-794.
57. Guetta V., Cannon R.O. III. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation. 93:1996;1928-1937.
58. Gilligan D.M., Quyyumi A.A., Cannon R.O. III. Effects of physiologic levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation. 89:1994;2545-2551.
59. Gilligan D.M., Badar D.M., Panza J.A., et al. Acute vascular effects of estrogen in postmenopausal women. Circulation. 90:1994;786-791.
60. Gilligan D.M., Badar D.M., Panza J.A., et al. Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women. Am J Cardiol. 75:1995;264-268.
61. Lieberman E.H., Gebhard M.D., Uehata A., et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med. 121:1994;936-941.
62. Cooke J.P., Andon N.A., Girerd X.J., et al. Arginine restores cholinergic relaxation of hypercholesterolemic rabbit thoracic aorta. Circulation. 83:1991;1057-1062.
63. Creager M.A., Gallagher S.J., Girerd X.J., et al. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 90:1992;1248-1253.
64. Drexler H., Zeiher A.M., Meinzer K., Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolemic patients by L-arginine. Lancet. 338:1991;1546-1550.
65. Dubois-Randé J.-L., Zelinsky R., Roudot F., et al. Effects of infusion of L-arginine into the left anterior descending coronary artery on acetylcholine-induced vasoconstriction of human atheromatous coronary arteries. Am J Cardiol. 70:1992;1269-1275.
66. Quyyumi A.A., Dakak N., Diodati J.G., et al. Effect of L-arginine on human coronary endothelium-dependent and physiologic vasodilation. J Am Coll Cardiol. 30:1997;1220-1227.
67. Clarkson P., Adams M.R., Powe A.J., et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest. 97:1996;1989-1994.
68. Kerth P.A., Vanhoutte P.M. Effect of perindoprilat on endothelium-dependent relaxations and contractions in isolated blood vessels. Am J Hypertens. 4:1991;226S-234S.
69. Bhoola K.D., Figueroa C.D., Worthy K. Bioregulation of kinins kallikreins, kininogens, and kininases . Pharmacol Rev. 44:1992;1-80.
70. Rajagopalan S., Kurz S., Münzel T., et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation contribution to alterations of vasomotor tone . J Clin Invest. 97:1996;1916-1923.
71. Mancini G.B.J., Henry G.C., Macaya C., et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease the TREND (Trial on Reversing ENdothelial Dysfunction) Study . Circulation. 94:1996;258-265.
72. Prasad A., Husain S., Mincemoyer R., et al. Coronary endothelial dysfunction in humans improves with angiotensin converting enzyme inhibition. (Abstr.) Circulation. 94:(suppl 1):1996;1-61.
73. Andrews T.C., Raby K., Barry J., et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation. 95:1997;324-328.